Non-COVID Admissions to the ICU After COVID Vaccination: A Multicenter Study.

Publication date: Oct 01, 2024

The vaccination drive for COVID-19 was launched in India after the authorization of ChAdOx1 nCov-19 (Covishield), an adenoviral vector vaccine, and BBV152 COVID-19 (Covaxin), an inactivated virus vaccine. As stated by the CDC, vaccine-related adverse events can happen. In this study, we aimed to assess the timing of the COVID vaccination and admission diagnosis and their effect on ICU mortality. The time from vaccination can help identify adverse events directly related to vaccination. Methods: A retrospective cohort study was conducted across four centers in India. Patients who took the first or second dose of any vaccines and were admitted with non-COVID illness to the ICU were included in the study. Patients were categorized based on the time interval from vaccination as ≤42 days or >42 days. The primary outcome was ICU mortality. The secondary outcomes were the length of ICU stay and duration of mechanical ventilation. A total of 175 patients were included in the study. The mean age was 53. 49 (15. 89) years, and 61. 14% were males. The ICU mortality was 24. 57% (18. 38% to 31. 63%). Thromboembolic events such as acute coronary syndrome (ACS), cerebrovascular accident (CVA), and mesenteric ischemia were seen in 7. 43%, 7. 43%, and 1. 14% of patients, respectively. Six patients (3. 43%) developed neuromuscular illness. The mortality was higher in patients >66 years, followed by ≤35 years of age when admitted ≤42 days of vaccination (p=0. 008). The mortality was higher in cerebrovascular disorders and was clinically significant (p66 years and ≤35 years when admitted within 42 days of COVID vaccination. Patients admitted with cerebrovascular diseases also had higher mortality.

Open Access PDF

Concepts Keywords
Accident bbv152
Bbv152 chadox1 ncov-19
Covid covaxin
Thromboembolic covid-19
Vaccination covishield
guillian barre syndrome
vaccination
vitt

Semantics

Type Source Name
disease MESH COVID-19
disease MESH acute coronary syndrome
disease MESH cerebrovascular accident
disease MESH mesenteric ischemia
disease MESH cerebrovascular disorders
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH Emergency
disease MESH syndrome
disease MESH thrombocytopenia
disease MESH complications
disease IDO process
disease MESH Diabetes mellitus
disease MESH Hypertension
disease MESH COPD
disease MESH Bronchial asthma
disease MESH Malignancy
disease MESH Chronic kidney disease
disease MESH Ischemic heart disease
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH sepsis
disease MESH myasthenia gravis
disease MESH polyradiculopathy
disease MESH bleeding
disease MESH Neuromuscular diseases
disease MESH coronary thrombosis
disease MESH causality
disease MESH myocarditis
disease MESH fatal outcomes
drug DRUGBANK Etoperidone
disease IDO country
disease MESH Thrombosis
disease MESH venous thrombosis
disease MESH thrombotic stroke
disease MESH Thromboembolism
disease MESH immune thrombocytopenia
disease MESH influenza
disease MESH death
disease MESH pericarditis

Original Article

(Visited 4 times, 1 visits today)